---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-090205"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:43:13.513768+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director William Meury resigns from Syndax board to become Incyte CEO

## Summary
- William Meury resigned from Syndax board effective June 24, 2025.
- Meury accepted roles of President, CEO, and board member at Incyte Corporation.
- Incyte is Syndax's collaboration partner for Niktimvo (axatilimab-csfr).
- Resignation not due to any disagreement with Syndax's operations or policies.

## SEC filing metadata
- accession: 0000950170-25-090205
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017025090205/0000950170-25-090205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017025090205/sndx-20250624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-090205
- JSON: https://secwatch.observer/filing/0000950170-25-090205.json
- Plain text: https://secwatch.observer/filing/0000950170-25-090205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.